“We are hosting the cure FA soiree on Saturday, June seventh At the Omni Hotel in Oklahoma City, and this event was born out ...

About DT-216P2 DT-216P2 is an improved formulation of a GeneTAC ® small molecule designed to specifically target the GAA repeat expansion mutation that is the underlying cause of FA and restore the ...

Early research shows that editing expanding trinucleotide repeats halts the lengthening process that causes neurological disease.

Lexeo Therapeutics announced positive interim data for LX2006 in Phase 1/2 studies targeting Friedreich ataxia (FA) cardiomyopathy, indicating surpassing results in frataxin expression and left ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended by the EMA’s human ...

Additional data presented demonstrate the potential use of RSwitch to solve cardiotoxicity challenges in gene therapy applications for the treatment of Friedreich's ataxia Data to be presented at ...

(RTTNews) - Biohaven Ltd. (BHVN) announced that the Division of Neurology 1 within FDA's Office of Neuroscience informed the company that they have extended the PDUFA date for the troriluzole new ...

Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial “From a ...